intravitreal Anti-VEGF injection — Competitive Intelligence Brief

intravitreal Anti-VEGF injection (intravitreal Anti-VEGF injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor. Area: Ophthalmology.

marketed VEGF inhibitor VEGF (Vascular Endothelial Growth Factor) Ophthalmology Small molecule

Target snapshot

intravitreal Anti-VEGF injection (intravitreal Anti-VEGF injection) — Seoul National University Bundang Hospital. Intravitreal anti-VEGF injection blocks vascular endothelial growth factor to inhibit abnormal blood vessel growth in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intravitreal Anti-VEGF injection TARGET	intravitreal Anti-VEGF injection	Seoul National University Bundang Hospital	marketed	VEGF inhibitor	VEGF (Vascular Endothelial Growth Factor)
Bevacizumab-awwb	Bevacizumab-awwb	Amgen	marketed	VEGF inhibitor monoclonal antibody / Bevacizumab biosimilar	VEGF (Vascular Endothelial Growth Factor)
pegaptanib sodium injection	pegaptanib sodium injection	Bausch & Lomb Incorporated	marketed	VEGF inhibitor (aptamer)	VEGF165 (vascular endothelial growth factor)
Rescue Intravitreal Aflibercept Injection	Rescue Intravitreal Aflibercept Injection	Southeast Retina Center, Georgia	marketed	VEGF inhibitor / Recombinant fusion protein	VEGF-A, VEGF-B, PlGF (placental growth factor)
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
Bevacizumab (Avastin®)	Bevacizumab (Avastin®)	Hanny Al-Samkari, MD	marketed	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)
Lucentis (Treat and extend)	Lucentis (Treat and extend)	Retinal Consultants of Arizona	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor class)

1. Hoffmann-La Roche · 2 drugs in this class
2. Genentech, Inc. · 1 drug in this class
3. Genzyme, a Sanofi Company · 1 drug in this class
4. Innostellar Biotherapeutics Co.,Ltd · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Pfizer · 1 drug in this class
7. Eli Lilly and Company · 1 drug in this class
8. Seoul National University Bundang Hospital · 1 drug in this class